Navigation Links
Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
Date:1/18/2008

BALTIMORE, Jan. 18 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow, as Vice President, Marketing and Alliance Management. In this role, Ms. Perrow will be responsible for leading Alba's marketing development strategy and program execution through product approval and commercialization. Ms. Perrow will also serve as a member of Alba's executive management leadership team.

"We are very pleased to announce that Ms. Perrow is joining Alba in this critical leadership role. Wendy is an accomplished executive with extensive experience in pharmaceutical marketing including both US and global product launches and programs to increase brand use and awareness," said Blake Paterson, M.D., Alba's Chief Executive Officer. "Her leadership in our brand creation and marketing efforts, and management of our corporate alliances will be essential for our success in developing AT-1001 (larazotide acetate) as the first drug for celiac disease," added Dr. Paterson.

"Alba is focused on discovering and commercializing novel therapies for patients with serious autoimmune and inflammatory conditions. It is wonderful to join this innovative organization that is dedicated to bringing new medicines to patients who need them and help change the course of disease," said Ms. Perrow.

Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, Ms. Perrow was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. Her experience ranges from oncology, bone marrow transplant, metabolic disorders, and renal disease. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in the areas of global marketing and U.S. marketing in the areas of Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. A skilled marketer, she has led U.S. and global initiatives for leading products that have significantly increased brand awareness and has launched medicines for unmet medical needs.

Ms. Perrow holds a bachelors degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to the development and commercialization of disease-modifying therapeutics to treat autoimmune and inflammatory diseases, drug delivery agents and mucosal vaccine adjuvants by exploiting its technology to regulate the assembly and disassembly of tight junctions in cell barriers throughout the body. Alba's lead compound, AT-1001 (Larazotide acetate), is targeted toward the treatment of Celiac Disease, Inflammatory Bowel Disease and Type 1 Diabetes.

Contact: Dr. Bernard McDonald

Phone: 410-319-0780

E-mail: info@albatherapeutics.com

Website: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
2. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
3. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
4. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
5. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
6. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
7. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
8. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
9. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
10. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
11. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 20, 2017 , ... Nipro Corporation (Osaka, ... Venture (JV) under which Nipro will receive exclusive marketing and sales rights for all ... best practices for hemodialysis patients in Japan, the new Nipro - Transonic JV is ...
(Date:1/21/2017)... Bioptix, Inc. (Nasdaq: ... January 14, 2017 the Board of Directors of the ... terminate certain employees associated with the September 2016 acquisition ... terminations on January 16, 2017 and terminations are expected ... pay severance benefits in certain circumstances of up to ...
(Date:1/20/2017)... ... 20, 2017 , ... The two newest companies to join the University City ... spin out from The Wistar Institute, and Sanguis, launched by a trio of students ... , Vironika is developing a treatment for a chronic viral infection and its ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):